Generated by AI
Collegium Pharmaceutical, Inc. is a specialty biopharmaceutical company focused on developing and commercializing medicines for pain management and attention-deficit/hyperactivity disorder (ADHD). Its current portfolio includes branded prescription products such as Xtampza ER, Belbuca, the Nucynta franchise, Jornay PM, and Symproic, serving patients with complex and chronic medical conditions. The company emphasizes differentiated drug-delivery technology and responsible pain-management therapies, with its business centered on the U.S. market. Collegium Pharmaceutical, Inc. also supports its products through commercial operations, market access, and patient support activities, making it a notable participant in branded specialty pharmaceuticals.
Website100 Technology Center Drive
Stoughton, MA, 02072
United States
The latest articles about COLL.
Summary of Jul 2's posts. Generated by AI.
Summary of Feb 20's posts. Generated by AI.
Summary of Jul 29's posts. Generated by AI.
Summary of Feb 14's posts. Generated by AI.
Investors talking about COLL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.